---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-157554"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2024-06-07T23:59:59+00:00"
generated_at: "2026-06-01T05:31:41.383073+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CEO J. Scott Wolchko assumes CFO role after Edward Dulac's resignation; stock plan expanded

## Summary
- CFO Edward Dulac resigned effective June 14, 2024; CEO J. Scott Wolchko appointed as CFO and principal financial/accounting officer.
- Wolchko previously served as CFO from company inception until August 2020; no change to his compensation.
- Stockholders approved amendment to 2022 Stock Option Plan, increasing available shares by 8,000,000 to 17,500,000 total.
- Other proposals passed: election of three Class II directors, ratification of EY, say-on-pay, officer exculpation amendment.
- Broker non-votes were ~6.7M on most items; say-on-pay passed with ~65.4M for vs 25.6M against.

## SEC filing metadata
- accession: 0001193125-24-157554
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2024-06-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312524157554/0001193125-24-157554-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312524157554/d839723d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-157554
- JSON: https://secwatch.observer/filing/0001193125-24-157554.json
- Plain text: https://secwatch.observer/filing/0001193125-24-157554.txt

## Key facts
- Executive change
  J. Scott Wolchko was appointed as Chief Financial Officer at FATE THERAPEUTICS INC.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On June 3, 2024, the board of directors (the “Board”) of Fate Therapeutics, Inc. (the “Company”) appointed J. Scott Wolchko, the Company’s President and Chief Executive Officer, to succeed Edward J. Dulac III as the Company’s Chief Financial Officer and also serve as the Company’s principal financial and accounting officer, effective immediately after Mr. Dulac’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312524157554/0001193125-24-157554-index.htm
- Executive change
  Edward J. Dulac III resigned as Chief Financial Officer at FATE THERAPEUTICS INC.
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Mr. Dulac provided notice of his resignation from his position as the Company’s Chief Financial Officer on May 30, 2024, which resignation shall be effective as of June 14, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000119312524157554/0001193125-24-157554-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.